The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium.
M. I. Milowsky
Research Funding - Novartis
A. M. Regazzi
No relevant relationships to disclose
I. R. Garcia-Grossman
No relevant relationships to disclose
A. Trout
No relevant relationships to disclose
A. Flaherty
No relevant relationships to disclose
S. Gerst
No relevant relationships to disclose
H. Al-Ahmadie
No relevant relationships to disclose
I. Ostrovnaya
No relevant relationships to disclose
D. F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; GlaxoSmithKline
Honoraria - Lilly
Research Funding - Amgen; Genentech; Genta